Incidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution Experience
暂无分享,去创建一个
[1] C. Fabian,et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion , 1990, Investigational New Drugs.
[2] R. Schilsky,et al. Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study , 2004, Cancer Chemotherapy and Pharmacology.
[3] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Buyse,et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] B. Reigner,et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] R. Diasio. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. , 1998, Oncology.
[7] B. Reigner,et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Pazdur,et al. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. , 1998, Anti-cancer drugs.
[9] D. Thamm,et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] B. Reigner,et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Hortobagyi,et al. Hand‐foot syndrome following prolonged infusion of high doses of vinorelbine , 1998, Cancer.
[12] T. Kuzel,et al. Hand‐foot syndrome associated with liposome‐encapsulated doxorubicin therapy , 1995, Cancer.
[13] D. V. Von Hoff,et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. , 1993, Journal of the National Cancer Institute.
[14] B. Baack,et al. Chemotherapy-induced acral erythema. , 1991, Journal of the American Academy of Dermatology.
[15] R. Weiss,et al. Pyroxidine for the Palmar-Plantar Erythrodysesthesia Syndrome , 1989 .
[16] S. M. Crawford,et al. Anthracycline-induced toxicity affecting palmar and plantar skin. , 1989, British Journal of Cancer.
[17] R. Weiss,et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. , 1989, Annals of internal medicine.
[18] N. Mulder,et al. A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Willemze,et al. Palmar-plantar skin changes and cytarabine. , 1985, Annals of internal medicine.
[20] M. Ratain,et al. Cancer chemotherapy and skin changes. , 1985, Annals of internal medicine.
[21] J. Lokich,et al. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. , 1984, Annals of internal medicine.
[22] W. Burgdorf,et al. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. , 1982, Annals of internal medicine.
[23] W. Grove. Statistical Methods for Rates and Proportions, 2nd ed , 1981 .
[24] J. Fleiss,et al. Statistical methods for rates and proportions , 1973 .
[25] P. György,et al. Vitamin B6 and Skin Lesions in Rats , 1939, Nature.